ACIU Earnings Results and History
AC Immune SA's earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- Revenue$1.3M +90.1% vs a year ago
- Net income−$21.2M
- EPS (GAAP)–
Filed Mar 13, 2026. The next earnings release shows here within a minute of filing.
Revenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| Jun 2025 | $1.3M | +90.1% | −1484.5% | −$21.2M | – | – |
| Jun 2024 | $687K | – | −3051.1% | −$22.8M | – | – |
| Dec 2022 | $1K | – | −1869700.0% | −$18.7M | – | −$17.4M |
| Sep 2022 | $3.9M | – | −342.2% | −$13.5M | – | −$13.7M |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $3.6M | −86.9% | −1940.1% | −$70.4M | – |
| Dec 31, 2024 | $27.3M | +84.5% | −191.8% | −$50.9M | – |
| Dec 31, 2023 | $14.8M | +276.1% | −362.3% | −$54.2M | – |
| Dec 31, 2022 | $3.9M | – | −1800.4% | −$70.8M | – |
| Dec 31, 2021 | $0 | – | – | −$73M | – |
Filings and dates
SEC EDGAR- Mar 13, 2026Quarterly report20-F All filings
Also see ACIU institutional ownership and the earnings calendar.
ACIU earnings FAQ
When is ACIU's next earnings date?
There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.
Is ACIU's revenue growing?
In the quarter ended Jun 30, 2025 revenue was $1.3M, up 90.1% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from AC Immune SA's own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.